PUBLISHER: The Business Research Company | PRODUCT CODE: 1763105
PUBLISHER: The Business Research Company | PRODUCT CODE: 1763105
Vectibix (panitumumab) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts
Vectibix (panitumumab) is a monoclonal antibody used to treat metastatic colorectal cancer (mCRC). It targets the epidermal growth factor receptor (EGFR), a protein found on the surface of certain cancer cells. By binding to EGFR, panitumumab prevents its activation by natural growth factors, thereby inhibiting the signaling pathways that promote cell division and tumor growth.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The key distribution channels for vectibix include hospital pharmacies and online pharmacies. Hospital pharmacies provide medications to both inpatients and outpatients within healthcare facilities as part of integrated medical care. The drug is primarily used for treating colorectal cancer and other cancer types, with end-users including hospitals, clinics, and ambulatory surgical centers.
The vectibix (panitumumab) market research report is one of a series of new reports from The Business Research Company that provides vectibix (panitumumab) market statistics, including vectibix (panitumumab) industry global market size, regional shares, competitors with a vectibix (panitumumab) market share, detailed vectibix (panitumumab) market segments, market trends and opportunities, and any further data you may need to thrive in the vectibix (panitumumab) industry. This vectibix (panitumumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The vectibix (panitumumab) market size is expected to see strong growth in the next few years. It will grow to $1,853.9 million in 2029 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to increasing prevalence of metastatic colorectal cancer (mcrc) globally, growing focus on personalized medicine, increasing healthcare spending in emerging markets, growing adoption of biologics in oncology, increasing focus on patient quality of life. Major trends in the forecast period include advancements in anti-EGFR therapies, partnerships and collaborations between pharmaceutical companies, integration of advanced diagnostic tools, development of companion diagnostics, adoption of next-generation sequencing.
The increasing prevalence of colorectal cancer is expected to drive the growth of the vectibix (panitumumab) market in the coming years. Colorectal cancer, which begins in the colon or rectum, is influenced by factors such as aging, genetic predispositions, and environmental influences. The rising incidence of colorectal cancer is linked to an aging population, better survival rates, and improved detection methods. Vectibix (panitumumab), a monoclonal antibody, targets and inhibits the epidermal growth factor receptor (EGFR) to slow tumor growth and progression in patients with wild-type KRAS tumors. This offers an effective treatment for patients who do not respond to conventional chemotherapy. According to the World Health Organization (WHO), the global burden of colorectal cancer is expected to increase significantly by 2040, with 3.2 million new cases annually, a 63% rise. This growing prevalence is poised to drive the demand for vectibix.
The rising demand for personalized medicine is a key factor propelling the growth of the vectibix (panitumumab) market. Personalized medicine tailors treatments based on individual patient characteristics, including genetic profiles. Advances in genomic technologies, improved understanding of molecular biology, and the availability of precision diagnostic tools have made personalized therapies more common. Vectibix is used as a personalized treatment for metastatic colorectal cancer by targeting the EGFR on cancer cells, particularly in patients whose tumors express wild-type EGFR. This targeted approach improves therapeutic efficacy and minimizes side effects. For example, in February 2023, the Personalized Medicine Coalition highlighted that the FDA approved several important indications for in vitro diagnostic testing, contributing to the rising demand for personalized medicine. This trend further supports the growth of the vectibix market.
A significant trend in the vectibix market is the development of molecular diagnostic products, such as companion diagnostic kits, which help identify the most suitable patients for targeted therapies. Companion diagnostic kits detect specific biomarkers or genetic mutations, ensuring that treatments like Vectibix are given to patients who are most likely to benefit. In October 2023, EntroGen Inc. received FDA approval for the CRCdx RAS Mutation Detection Kit as a companion diagnostic for Vectibix. This kit, which detects mutations in KRAS and NRAS genes, helps clinicians identify patients who would benefit from Vectibix, ensuring more effective treatment while minimizing unnecessary side effects and costs. This trend towards personalized diagnostics is enhancing the precision of Vectibix therapy and contributing to the market's growth.
The Key player operating in the vectibix (panitumumab) market is Amgen Inc.
North America was the largest region in the vectibix (panitumumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in vectibix (panitumumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vectibix (panitumumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The vectibix (panitumumab) market consists of sales of chemotherapy combination products, nutritional supplements, supportive care medications and related products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Vectibix (panitumumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on vectibix (panitumumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for vectibix (panitumumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vectibix (panitumumab) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Distribution Channel: Hospital Pharmacies; Online Pharmacies
- 2) By Application: Colorectal Cancer Treatment; Other Cancer Treatments
- 3) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers
- Companies Mentioned: Amgen Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Vectibix (panitumumab) Market Characteristics
3. Vectibix (panitumumab) Market Biologic Drug Characteristics
- 3.1. Molecule Type
- 3.2. Route Of Administration (ROA)
- 3.3. Mechanism Of Action (MOA)
- 3.4. Safety And Efficacy
4. Vectibix (panitumumab) Market Trends And Strategies
5. Vectibix (panitumumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
6. Global Vectibix (panitumumab) Growth Analysis And Strategic Analysis Framework
- 6.1. Global Vectibix (panitumumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 6.2. Analysis Of End Use Industries
- 6.3. Global Vectibix (panitumumab) Market Growth Rate Analysis
- 6.4. Global Vectibix (panitumumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 6.5. Global Vectibix (panitumumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 6.6. Global Vectibix (panitumumab) Total Addressable Market (TAM)
7. Global Vectibix (panitumumab) Market Pricing Analysis & Forecasts
8. Vectibix (panitumumab) Market Segmentation
- 8.1. Global Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacies
- Online Pharmacies
- 8.2. Global Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Colorectal Cancer Treatment
- Other Cancer Treatments
- 8.3. Global Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Clinics
- Ambulatory Surgical Centers
9. Global Vectibix (panitumumab) Market Epidemiology Of Clinical Indications
- 9.1. Drug Side Effects
- 9.2. Incidence And Prevalence of Clinical Indications
10. Vectibix (panitumumab) Market Regional And Country Analysis
- 10.1. Global Vectibix (panitumumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. Global Vectibix (panitumumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Asia-Pacific Vectibix (panitumumab) Market
- 11.1. Asia-Pacific Vectibix (panitumumab) Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 11.2. Asia-Pacific Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Asia-Pacific Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Asia-Pacific Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. China Vectibix (panitumumab) Market
- 12.1. China Vectibix (panitumumab) Market Overview
- 12.2. China Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 12.3. China Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 12.4. China Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
13. India Vectibix (panitumumab) Market
- 13.1. India Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. India Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. India Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. Japan Vectibix (panitumumab) Market
- 14.1. Japan Vectibix (panitumumab) Market Overview
- 14.2. Japan Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. Japan Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. Japan Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Australia Vectibix (panitumumab) Market
- 15.1. Australia Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.2. Australia Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Australia Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. South Korea Vectibix (panitumumab) Market
- 16.1. South Korea Vectibix (panitumumab) Market Overview
- 16.2. South Korea Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. South Korea Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.4. South Korea Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Western Europe Vectibix (panitumumab) Market
- 17.1. Western Europe Vectibix (panitumumab) Market Overview
- 17.2. Western Europe Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Western Europe Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.4. Western Europe Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. UK Vectibix (panitumumab) Market
- 18.1. UK Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. UK Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. UK Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Germany Vectibix (panitumumab) Market
- 19.1. Germany Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Germany Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Germany Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. France Vectibix (panitumumab) Market
- 20.1. France Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. France Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. France Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Vectibix (panitumumab) Market
- 21.1. Eastern Europe Vectibix (panitumumab) Market Overview
- 21.2. Eastern Europe Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. North America Vectibix (panitumumab) Market
- 22.1. North America Vectibix (panitumumab) Market Overview
- 22.2. North America Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. North America Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.4. North America Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. USA Vectibix (panitumumab) Market
- 23.1. USA Vectibix (panitumumab) Market Overview
- 23.2. USA Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. USA Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. USA Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. Canada Vectibix (panitumumab) Market
- 24.1. Canada Vectibix (panitumumab) Market Overview
- 24.2. Canada Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. Canada Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. Canada Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. South America Vectibix (panitumumab) Market
- 25.1. South America Vectibix (panitumumab) Market Overview
- 25.2. South America Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. South America Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. South America Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. Middle East Vectibix (panitumumab) Market
- 26.1. Middle East Vectibix (panitumumab) Market Overview
- 26.2. Middle East Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. Middle East Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. Middle East Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Africa Vectibix (panitumumab) Market
- 27.1. Africa Vectibix (panitumumab) Market Overview
- 27.2. Africa Vectibix (panitumumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Africa Vectibix (panitumumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.4. Africa Vectibix (panitumumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Vectibix (panitumumab) Market Competitive Landscape And Company Profiles
- 28.1. Vectibix (panitumumab) Market Competitive Landscape
- 28.2. Vectibix (panitumumab) Market Company Profiles
- 28.2.1. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
29. Global Vectibix (panitumumab) Market Pipeline Analysis
- 29.1. High Level Clinic Trail Information
30. Global Vectibix (panitumumab) Market Competitive Benchmarking And Dashboard
31. Key Mergers And Acquisitions In The Vectibix (panitumumab) Market
32. Recent Developments In The Vectibix (panitumumab) Market
33. Vectibix (panitumumab) Market High Potential Countries, Segments and Strategies
- 33.1 Vectibix (panitumumab) Market In 2029 - Countries Offering Most New Opportunities
- 33.2 Vectibix (panitumumab) Market In 2029 - Segments Offering Most New Opportunities
- 33.3 Vectibix (panitumumab) Market In 2029 - Growth Strategies
- 33.3.1 Market Trend Based Strategies
- 33.3.2 Competitor Strategies
34. Appendix
- 34.1. Abbreviations
- 34.2. Currencies
- 34.3. Historic And Forecast Inflation Rates
- 34.4. Research Inquiries
- 34.5. The Business Research Company
- 34.6. Copyright And Disclaimer
